ATMA

ATMA Expands Practitioner In-Person Clinical Training to Bridge with Psychedelic-Assisted Therapy Clinical Practice

Retrieved on: 
Thursday, April 11, 2024
Psilocybin, CENA, Therapy, Mat, PAT, AB, MAPS, MDMA, ATMA, Tran, Student, Growth, Nursing

This expansion includes a significant increase in in-person clinical training opportunities, as well as the bridging of training and clinical practice initiatives.

Key Points: 
  • This expansion includes a significant increase in in-person clinical training opportunities, as well as the bridging of training and clinical practice initiatives.
  • Since 2021, ATMA has been committed to providing training to therapists and practitioners globally, aiming to foster greater participation in the field of PaT.
  • However, beyond training, ATMA's overarching vision has always been to equip therapists and practitioners with the essential infrastructure needed to deliver psychedelic-assisted therapy effectively following their training.
  • Consequently, ATMA has launched its in-person clinical training workshop on MDMA-assisted therapy utilizing the MAPS protocol, commencing in May 2024.

ATMA CENA Psychedelic Healthcare Solutions Opens Psychedelic-Assisted Therapy Clinic in Calgary and Provides Update of its Clinic Network

Retrieved on: 
Thursday, March 14, 2024
Organization, Kat, Growth, Surgeon, Entrepreneurship, Patient, AB, PHS, ATMA, CENA, Transcranial magnetic stimulation, Mental health, Tran, SAP, PAT, Psilocybin, Psychedelic drug, Ecosystem, Safety, MDMA, Physician, Special access program, Nursing

CALGARY, AB, March 14, 2024 /PRNewswire/ - ATMA CENA Psychedelic Healthcare Solutions (PHS) is a collaboration of ATMA Journey Centers Inc. ("ATMA"), Cena Life Inc ., and partners across Canada to advance and expand access to psychedelic-assisted therapy (PaT) through the establishment of a clinic network.

Key Points: 
  • CALGARY, AB, March 14, 2024 /PRNewswire/ - ATMA CENA Psychedelic Healthcare Solutions (PHS) is a collaboration of ATMA Journey Centers Inc. ("ATMA"), Cena Life Inc ., and partners across Canada to advance and expand access to psychedelic-assisted therapy (PaT) through the establishment of a clinic network.
  • ATMA CENA PHS is pleased to announce commencement of the Calgary Clinic operations and its new location in Edmonton.
  • ATMA CENA Psychedelic Therapy Edmonton – 5555 Calgary Trail NW, Edmonton, AB
    ATMA CENA Psychedelic Therapy Calgary – 742 – 42nd Ave SE, Calgary, AB
    ATMA CENA Psychedelic Therapy Toronto – Woodbridge, Vaughan
    Utilizing Alberta's Psychedelic Drug Treatment Service Standards and the College of Physicians and Surgeons of Alberta Accreditation Program as foundational principles, ATMA CENA clinics will aim to support the establishment of the necessary infrastructure that enables standardized care.
  • In the delivery of PaT across Canada, ATMA CENA PHS aims to support care that is safe, operationally consistent, efficient, effective, and regulation compliant.

ATMA and Cena Life Launch Nationwide Psychedelic-Assisted Therapy Healthcare Network

Retrieved on: 
Thursday, December 7, 2023
Psilocybin, KAP, Depression, Safety, Nursing, SAP, Transcranial magnetic stimulation, Physician, MDMA, Surgeon, Kat, AB, Patient, Ecosystem, Registered nurse, City, ATMA, Special access program, Anxiety, PTSD, Psychedelic drug, Therapy, PAT

CALGARY, AB, Dec. 7, 2023 /PRNewswire/ - ATMA Journey Centers Inc. ("ATMA") and Cena Life , forefront leaders in advancing psychedelic-assisted therapy (PaT) are  pleased to announce the opening of a  licensed Calgary Clinic and the establishment of the Psychedelic-Assisted Therapy Healthcare Network, a national clinical network for the emerging psychedelic-assisted therapy sector.

Key Points: 
  • CALGARY, AB, Dec. 7, 2023 /PRNewswire/ - ATMA Journey Centers Inc. ("ATMA") and Cena Life , forefront leaders in advancing psychedelic-assisted therapy (PaT) are  pleased to announce the opening of a  licensed Calgary Clinic and the establishment of the Psychedelic-Assisted Therapy Healthcare Network, a national clinical network for the emerging psychedelic-assisted therapy sector.
  • Like the evolving services in the Cena Life practice in Edmonton, the Calgary clinic will offer KaT, rTMS, SAP application support as well as regular psychological counselling services.
  • Together, we aim to create a network that prioritizes patient well-being while fostering a collaborative and supportive environment for practitioners.
  • Practitioners wishing to join The Psychedelic Healthcare Network are encouraged to take the required training for PaT in advance of practice.

Kratos Defense Self-Driving Trucks are on the Road Across the United States, Increasing Worker Safety and Addressing Workforce Shortfalls

Retrieved on: 
Monday, May 8, 2023
Maintenance, State, Kratos Defense & Security Solutions, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Department of Defense, ODD, Attention, BIL, Civic technology companies, Kratos, American Trucking Associations, DOD, Navigation Data Standard, Plus (autonomous trucking), United States Department of State, DOT, Supply chain, Machine learning, Risk, Algorithm, SAN, Artificial intelligence, Mobility, Technology company, Safety, ATMA, SMART, TMA, Renewable energy, Rail transport, Defense, Transport

Today, Kratos has multiple self-driving trucks deployed on the road across the United States supporting new deployment use cases and territories.

Key Points: 
  • Today, Kratos has multiple self-driving trucks deployed on the road across the United States supporting new deployment use cases and territories.
  • Kratos deploys self-driving trucks to solve real-world workforce and safety issues of today burdening critical Transportation and Supply Chain operations.
  • This approach makes the application of driverless trucks achievable to effectively any municipality, organization, or company operating trucks today.
  • Addressing this issue, Kratos’ driverless technology is strategically deployed to support integrated end-to-end supply chain activity achieving industry safety and operational goals.

ATMA to Provide Psychedelic-Assisted Therapy Training in French and Spanish in the Fall

Retrieved on: 
Thursday, May 4, 2023
Psilocybin, AB, Language, Mental, TCS, COVID-19, Chansons pour les pieds, SUD, Sindicato de Médicos de Asistencia Pública v Conselleria de Sanidad y Consumo de la Generalidad Valenciana, ATMA, Tongue, MDMA, TDM, Nursing

CALGARY, AB, May 4, 2023 /PRNewswire/ - ATMA Journey Centers Inc. ("ATMA"), Canada's leading psychedelic-assisted therapy training provider, will roll out the first full psychedelic training program in French and Spanish, highly focused on psilocybin and MDMA , this September.

Key Points: 
  • CALGARY, AB, May 4, 2023 /PRNewswire/ - ATMA Journey Centers Inc. ("ATMA"), Canada's leading psychedelic-assisted therapy training provider, will roll out the first full psychedelic training program in French and Spanish, highly focused on psilocybin and MDMA , this September.
  • To date, almost all psychedelic-assisted therapy training available has been in English, which excludes many interested healthcare providers from participating.
  • ATMA continues to move the psychedelic therapy revolution forward with inclusivity and encourages more healthcare providers to participate in the field of psychedelic therapy.
  • ATMA's French and Spanish program content is designed for all healthcare providers including therapists and prescribers alike, as there will be multiple roles to fill in order to provide safe and effective psychedelic-assisted therapy.

Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists

Retrieved on: 
Tuesday, February 7, 2023
MDMA, Safety, Trial of the century, ATMA, FRA, Health Canada, CTA, Blood pressure, Diathesis–stress model, Physician, Patient, Partnership, Clinical trial, CSE, Hope, GMP, FOR, Temperature, ECG, Heart rate, Pharmaceutical industry, Medicine

Both drug candidates are scheduled to be administered in the clinical trial and will be manufactured in-house at Optimi’s 20,000 square foot facilities in Princeton, British Columbia.

Key Points: 
  • Both drug candidates are scheduled to be administered in the clinical trial and will be manufactured in-house at Optimi’s 20,000 square foot facilities in Princeton, British Columbia.
  • ATMA is currently the only Canadian organization that has completed a successful Phase I safety trial with natural psilocybin in healthy therapists.
  • Participants will receive either 25mg of natural psilocybin and a placebo, 125mg of MDMA and a placebo, or 25mg of natural psilocybin in combination with MDMA (50mg, 80mg, or 125mg).
  • Optimi has set the important goal of using its operational strength and end-to-end capabilities to tackle the global mental health crisis in 2023 and beyond.

Alejandro Dabdoub is recognized by Continental Who's Who

Retrieved on: 
Friday, September 30, 2022
Sun, Wendell Pritchett, Business administration, Partner, ATMA, Investment, Wharton School of the University of Pennsylvania, London Business School, Harvard University, Entrepreneurship, Finance, Art, PR Newswire, List, Winning, University, La taverna della libertà, Bachelor of Business Administration, Continental, Security (finance)

HOUSTON, Sept. 30, 2022 /PRNewswire/ -- Alejandro Dabdoub is being recognized by Continental Who's Who as a Top Executive for his professional excellence in the Financial and Entrepreneurial fields and for his outstanding achievements at Allied Orion.

Key Points: 
  • HOUSTON, Sept. 30, 2022 /PRNewswire/ -- Alejandro Dabdoub is being recognized by Continental Who's Who as a Top Executive for his professional excellence in the Financial and Entrepreneurial fields and for his outstanding achievements at Allied Orion.
  • Alejandro Dabdoub is a Partner at Allied Orion, backed by over 20 years of industry knowledge.
  • Mr. Dabdoub is a recently published author, having written his first book, Winning: The Art of Becoming an American Investor in 2020.
  • Mr. Dabdoub has been recently recognized with a profile feature on PRNewswire.com and as a Marquis Who's Who Top Executive of 2021.

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Retrieved on: 
Thursday, September 22, 2022
Temperature, FRA, Safety, Blood pressure, FDA, Food, ATMA, Psilocybin, CTA, Company, Growth, MDMA, BioCompute Object, Partnership, Industry, Harder, FOR, Patient, Clinical trial, Attention, Multidisciplinary Association for Psychedelic Studies, Breakthrough therapy, Health Canada, CSE, Letter, Heart rate, Leadership, ECG, Substance abuse, GLOBE, Phobia, Food and Drug Administration Amendments Act of 2007, PTSD, Social anxiety, Pharmaceutical industry

Optimi CEO, Bill Ciprick, says the goal of the clinical trial is to acquire data, including blood pressure, temperature, heart rate, and ECG readings, for Optimis proprietary formulation using natural EU-GMP psilocybin and MDMA.

Key Points: 
  • Optimi CEO, Bill Ciprick, says the goal of the clinical trial is to acquire data, including blood pressure, temperature, heart rate, and ECG readings, for Optimis proprietary formulation using natural EU-GMP psilocybin and MDMA.
  • Coming off the success of ATMAs recently completed Phase I psilocybin trial and a No Objection Letter to conduct its N-500 Phase II psilocybin clinical trial on frontline healthcare professionals, were excited to officially begin the process, he added.
  • ATMA is currently the only Canadian organization that has received approval from Health Canada to conduct a Phase I safety trial with psilocybin in healthy therapists, which it completed last month.
  • Optimis plan for commercialization involves the Company being an active leader in meeting therapist demand for natural EU-GMP psilocybin and MDMA.

Optimi Health Finalizes Partnership and Psilocybin Supply Agreement With ATMA Journey Centers

Retrieved on: 
Wednesday, June 8, 2022
Education, Company, CSE, Research, FOR, FRA, CEO, Partnership, Palliative care, Growth, GLOBE, Patient, EU, Health, ATMA, Learning, United States Public Health Service, Psilocybin, Medicine, Pharmaceutical industry

The Company has finalized an agreement which will supply psilocybin products to ATMA for future therapist initiatives and supply requirements.

Key Points: 
  • The Company has finalized an agreement which will supply psilocybin products to ATMA for future therapist initiatives and supply requirements.
  • Few organizations have made as significant a contribution in recent years to the evolving regulatory conversation around psilocybin-assisted therapy as ATMA Journey Centers, said Bill Ciprick, CEO of Optimi Health.
  • Optimi Health is looking forward to opportunities presented by this partnership with ATMA to advance the knowledge base of trained psychedelic therapists by providing learning experiences and real-world data derived from the direct administration of a natural psilocybin product.
  • Optimi Health Corp. is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.

Alejandro Dabdoub is recognized by Continental Who's Who

Retrieved on: 
Tuesday, June 7, 2022
PR Newswire, Wendell Pritchett, Entrepreneurship, Investment, List, Partner, Winning, Business administration, La taverna della libertà, Multimedia, University, Harvard University, Pinnacle, Bangladesh Infrastructure Finance Fund Limited, Finance, London Business School, Art, ATMA, Financial technology, Sun, Bachelor of Business Administration, Continental, Wharton School of the University of Pennsylvania, Real estate development, Security (finance)

HOUSTON, Texas, June 6, 2022 /PRNewswire/ -- Alejandro Dabdoub is being recognized by Continental Who's Who as a Top Pinnacle Executive for his outstanding work in the Financial and Entrepreneurial fields and for his achievements at Allied Orion.

Key Points: 
  • HOUSTON, Texas, June 6, 2022 /PRNewswire/ -- Alejandro Dabdoub is being recognized by Continental Who's Who as a Top Pinnacle Executive for his outstanding work in the Financial and Entrepreneurial fields and for his achievements at Allied Orion.
  • Alejandro Dabdoub is a Partner at Allied Orion, backed by over twenty years of industry knowledge.
  • Mr. Dabdoub began his education at the University of New Orleans, graduating with a Bachelor of Business Administration degree in Finance in 2001.
  • Mr. Dabdoub has been recently recognized with a profile feature on PRNewswire.com and as a Marquis Who's Who Top Executive of 2021.